Abstract
BackgroundSialyltransferase I (ST6Gal-I) is an enzyme involved in tumor metastasis that processes sialic acid precursors into their mature form, enabling them to regulate gene expression. However, the effect of ST6Gal-I on the biological behavior of cancer cells remain unclear. This study was the first to demonstrate the influence of ST6Gal-I on cisplatin sensitivity in cervical cancer cells.MethodsKnockdown of ST6Gal-I was performed by shRNA and HeLa cells combination with cisplatin were tested.ResultsWe showed that down-regulation of ST6Gal-I promoted cell apoptosis and inhibited proliferation and invasion in cervical cancer cells. Knockdown of ST6Gal-I by RNA interference increased the sensitivity of HeLa cells to cisplatin in vitro, and reduced tumor volume and suppressed subcutaneous tumor growth in response to cisplatin treatment in a xenograft mouse model in vivo.ConclusionsThe results provide new information that ST6Gal-I plays an important role in several biological or pathological processes including drug resistance in cervical cancer and may be a potential therapeutic target to improve the response to chemotherapy in cervical cancer patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-2981-y) contains supplementary material, which is available to authorized users.
Highlights
Sialyltransferase I (ST6Gal-I) is an enzyme involved in tumor metastasis that processes sialic acid precursors into their mature form, enabling them to regulate gene expression
Cell lines and culture conditions The cervical cancer cell line HeLa was purchased from the China Center for Type Culture Collection (CCTCC; Shanghai, China) and cultured in Dulbecco's Modified Eagle's Medium (DMEM)-low sugar (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA), 100 U/ml penicillin, and 100 μg/ml streptomycin (Gibco BRL,Grand Island,NY, USA) at 37 °C in a humidified atmosphere of 5% CO2
Effect of DDP on HeLa cells viability DDP inhibited HeLa cells proliferation in a dose-dependent manner starting at a concentration of 0.5 μmol/L
Summary
Sialyltransferase I (ST6Gal-I) is an enzyme involved in tumor metastasis that processes sialic acid precursors into their mature form, enabling them to regulate gene expression. The effect of ST6Gal-I on the biological behavior of cancer cells remain unclear. This study was the first to demonstrate the influence of ST6Gal-I on cisplatin sensitivity in cervical cancer cells. Cervical cancer is the second largest class of malignant tumors for women, and it endangers women's health, especially in developing countries [1]. Approximately 500,000 new cases of cervical cancer are reported annually and approximately 230,000 women die of cervical cancer each year [2]. According to statistical data from the International Agency for Research on Cancer (IARC), in 2012 cervical cancer was the fourth most prevalent type of malignancy (62,000 new cases and 30,000 deaths) in Chinese women [3]. The traditional treatment of cervical cancer is surgery or radiation therapy [4]. Despite significant improvements in surgical techniques and radiotherapy for the treatment of
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
